## Quality ID #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)

#### 2024 COLLECTION TYPE:

MIPS CLINICAL QUALITY MEASURES (CQMS)

#### **MEASURE TYPE:**

Process - High Priority

#### **DESCRIPTION:**

Percentage of adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment.

#### **INSTRUCTIONS:**

This measure is to be submitted a minimum of <u>once per performance period</u> for all adults aged 18 years and older with pharmacotherapy for OUD seen during the measurement period that meet additional denominator criteria described below. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**NOTE:** Patient encounters for this measure conducted via telehealth (including but not limited to encounters coded with GQ, GT, 95, POS 02, POS 10) are allowable.

#### **Measure Submission Type:**

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third-party intermediaries. The listed denominator criteria are used to identify the intended population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third-party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third-party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

#### **DENOMINATOR:**

Adults aged 18 years and older who had a qualifying encounter during the performance year, and a diagnosis of OUD and pharmacotherapy for OUD during the denominator identification period

Eligibility to submit results for a patient requires a qualifying encounter in the performance year, i.e., between January 1, 2024, and December 31, 2024. Solely administering or prescribing OUD medication does not convey eligibility to submit.

If a patient has a qualifying encounter within the performance year, the patient is included in the denominator, if the following criteria are met in the denominator identification period between July 1, 2023, and June 30, 2024:

- Have a diagnosis of OUD
- Receive pharmacotherapy for OUD

#### **Definitions:**

**Qualifying Encounter** – Encounter during the performance year **Pharmacotherapy for OUD** –

- Buprenorphine
- Buprenorphine (extended-release injectable)

- Naltrexone (oral)
- Buprenorphine/naloxone
- Methadone
- Naltrexone (extended-release injectable)

**Denominator Identification Period** – The period in which eligible adults receive pharmacotherapy for OUD. The denominator identification period is defined as the 12-month period from 07/1/ 2023 to 6/30/ 2024. The denominator identification period includes the first six months of the reporting year and the last six months of the previous year to ensure that all included patients can be observed for at least 180 days of treatment in the reporting year. Patients started on treatment in the second half of the reporting year will be included in the denominator of the subsequent year. The patient must have at least one OUD medication and one visit with an OUD diagnosis during the denominator identification period to be eligible for the measure.

#### **Denominator Criteria (Eligible Cases):**

Adults aged ≥ 18 years on date of qualifying encounter

#### AND

**Diagnosis of OUD:** F11.10, F11.120, F11.121, F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.21, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29, F11.90, F11.920, F11.921, F11.922, F11.929, F11.93, F11.94, F11.950, F11.951, F11.959, F11.981, F11.982, F11.988, F11.99

#### **AND**

**Encounter during the measurement period (CPT or HCPCS):** 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99281, 99282, 99283, 99284, 99285, 99291, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350, G0402, G0438, G0439

#### AND

Adults currently taking pharmacotherapy for OUD: M1032

#### NUMERATOR:

Adults in the denominator who have at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days

**NUMERATOR NOTE:** Numerator compliance is expected to be determined within an 18-month period that includes the measurement period and the 6 months prior to the measurement period (07/01/2023–12/31/2024).

## Numerator Options:

Performance Met: Adults who have at least 180 days of continuous

pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days

(M1034)

OR

**Denominator Exception:** Adults who are deliberately phased out of

Medication Assisted Treatment (MAT) prior to 180

days of continuous treatment (M1035)

OR

Performance Not Met: Adults who have not had at least 180 days of

continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than

seven days (M1036)

#### **RATIONALE:**

Continuous pharmacotherapy for OUD is identified on the basis of the days covered by the days' supply of all prescription claims for any OUD medication (see list below) or number of days for which the drug was dispensed in a physician office or treatment center with the exceptions noted in this paragraph. The period of continuous pharmacotherapy starts on the day the first claim for an OUD medication is filled/supplied (index date) and lasts through the days' supply of the last claim for an OUD medication. To meet the 180-day requirement and be eligible for the measure, the date on the first claim for an OUD medication must fall at least 180 days before the end of the measurement period. For claims with a days' supply that extends beyond the end of the measurement period, count only the days for which the drug was available to the individual during the measurement period. If two or more prescription claims occur on the same day or overlap, the surplus based on the days' supplies accumulates over all prescriptions. However, if another claim is submitted after a claim for an injectable OUD medication or an oral OUD medication that is dispensed in an office or treatment center, the surplus from the day's supply for the injectable or office-dispensed medication is not retained.

An individual is considered to have continuous pharmacotherapy with OUD medication if there is no treatment gap of more than seven days. A gap is defined as a period during which the individual does not have oral OUD medication available based on the days' supply or is more than 7 days overdue for having an injection or implantation of an extended-release OUD medication.

#### **OUD Medication List**

- Buprenorphine
- Buprenorphine (extended-release injectable)
- Naltrexone (oral)
- Buprenorphine/naloxone
- Methadone
- Naltrexone (extended-release injectable)

Justification of Measure Definition: We define treatment continuity as (1) receiving at least 180 days of treatment and (2) no gaps in medication use of more than 7 days.

Our definition of minimum duration is based on the fact that the FDA registration trials for OUD drugs studied the effect of treatment over three to six months (US FDAa, undated; US FDAb, undated), and we have no evidence for effectiveness of shorter durations. In addition, several recommendations support a minimum six-month treatment period as the risk of relapse is the highest in the first 6-12 months after start of opioid abstinence (US FDAa, undated; US FDAb, undated; US DHHS, 2015). Longer treatment duration is associated with better outcomes compared to shorter treatments and the best outcomes have been observed among patients in long-term methadone maintenance programs ("Effective medical treatment of opiate addiction", 1998; Gruber et al., 2008; Moos et al., 1999; NIDA, 1999; Ouimette et al., 1998; Peles et al., 2013). Studies with long-term follow-up suggest that ongoing pharmacotherapy is associated with improved odds of opioid abstinence (Hser et al., 2015; Weiss et al., 2015). We did not specify a maximum duration of treatment, as no upper limit for duration of treatment has been empirically established (US DHHS, 2015).

The rationale for using a treatment gap of more than seven days in our definition is that the measure includes three active ingredients with different pharmacological profiles. There is substantial evidence for an elevated mortality risk immediately after treatment cessation (Cornish et al., 2010; Cousins et al., 2016; Davoli et al, 2007; Degenhardt et al., 2009; Gibson & Degenhardt, 2007; Pierce et al., 2016). Research suggests that methadone tolerance is lost after three days and this three-day threshold has been used in other observational methadone studies and in developing a United Kingdom treatment guideline which recommends revaluating patients for intoxication and withdrawal after a three-day methadone treatment gap (Cousins et al., 2016; Cousins et al., 2011; "Drug Misuse and Dependence— Guidelines on Clinical Management", 1999). Across all the medications, the mortality risk is highest in the first four weeks out of treatment, with many studies showing an increase in mortality in days 1-14 after treatment cessation.

## **CLINICAL RECOMMENDATION STATEMENTS:**


This is a process measure as it is quantifying medication compliance for a specific period of time and not abstinence from addictive use of opioids. By looking at adherence or continuity of pharmacotherapy for opioid use disorder, we are touching on an intermediate outcome as well. As such, no clinical recommendations are included.

## **COPYRIGHT:**

© 2020 RAND Corporation, CPT® contained in the Measure specifications is copyright 2004-2023 American Medical Association. ICD-10 is copyright 2023 World Health Organization. All Rights Reserved.

## 2024 Clinical Quality Measure Flow for Quality ID #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.



<sup>\*</sup> See the posted measure specification for specific coding and instructions to submit this measure. NOTE: Submission Frequency: Patient-Process

CPT only copyright 2023 American Medical Association. All rights reserved.
The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

# 2024 Clinical Quality Measure Flow Narrative for Quality ID #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)

**Disclaimer:** Refer to the measure specification for specific coding and instructions to submit this measure.

- 1. Start with Denominator
- 2. Check Adults aged greater than or equal to 18 years on date of qualifying encounter.
  - a. If Adults aged greater than or equal to 18 years on date of qualifying encounter equals No, do not include in Eligible Population/Denominator. Stop processing.
  - b. If Adults aged greater than or equal to 18 years on date of qualifying encounter equals Yes, proceed to check Diagnosis of OUD as listed in the Denominator\*.
- 3. Check Diagnosis of OUD as listed in the Denominator\*:
  - a. If Diagnosis of OUD as listed in the Denominator\* equals No, do not include in Eligible Population/Denominator. Stop processing.
  - b. If Diagnosis of OUD as listed in the Denominator\* equals Yes, proceed to check Encounter during the measurement period as listed in the Denominator\*.
- 4. Check Encounter during the measurement period as listed in the Denominator\*:
  - a. If Encounter during the measurement period as listed in the Denominator\* equals No, do not include in Eligible Population/Denominator. Stop processing.
  - b. If Encounter during the measurement period as listed in the Denominator\* equals Yes, proceed to check Adults currently taking pharmacotherapy for OUD.
- 5. Check Adults currently taking pharmacotherapy for OUD:
  - a. If Adults currently taking pharmacotherapy for OUD equals No, do not include in Eligible Population/Denominator. Stop processing.
  - b. If Adults currently taking pharmacotherapy for OUD equals Yes, include in Eligible Population/Denominator.
- 6. Denominator Population:
  - Denominator Population is all Eligible Patients in the Denominator. Denominator is represented
    as Denominator in the Sample Calculation listed at the end of this document. Letter d equals
    80 patients in the Sample Calculation.
- 7. Start Numerator
- 8. Check Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days:
  - a. If Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days equals Yes, include in Data Completeness Met and Performance Met.

- Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 patients in the Sample Calculation.
- b. If Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days equals No, proceed to check Adults who are deliberately phased out of Medication Assisted Treatment (MAT) prior to 180 days of continuous treatment.
- 9. Check Adults who are deliberately phased out of Medication Assisted Treatment (MAT) prior to 180 days of continuous treatment:
  - a. If Adults who are deliberately phased out of Medication Assisted Treatment (MAT) prior to 180 days of continuous treatment equals Yes, include in Data Completeness Met and Denominator Exception.
    - Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation.
  - b. If Adults who are deliberately phased out of Medication Assisted Treatment (MAT) prior to 180 days of continuous treatment equals No, proceed to check Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days.
- 10. Check Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days:
  - a. If Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days equals Yes, include in Data Completeness Met and Performance Not Met.
    - Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 10 patients in the Sample Calculation.
  - b. If Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than seven days equals No, proceed to check Data Completeness Not Met.
- 11. Check Data Completeness Not Met:
  - If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

#### Sample Calculations

Data Completeness equals Performance Met (a equals 50 patients) plus Denominator Exception (b equals 10 patients) plus Performance Not Met (c equals 10 patients) divided by Eligible Population/Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a equals 50 patients) divided by Data Completeness Numerator (70 patients) minus Denominator Exception (b equals 10 patients). All equals 50 patients divided by 60 patients. All equals 83.33 percent.

\* See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.